Medtronic plc (MDT) Receives ‘Analyst’ Rating

Medtronic plc (MDT) has an average broker rating of 1.78, which is interpreted as a Buy, as rated by 20 equity analysts. Nonetheless, 12 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 5 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Medtronic plc (MDT) : The consensus price target for Medtronic plc (MDT) is $91.71 for the short term with a standard deviation of $11.28. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $104, however, the pessimist price target for the company is $56.


Also, Major Brokerage house, Jefferies maintains its ratings on Medtronic plc (NYSE:MDT). In the latest research report, Jefferies raises the target price from $93 per share to $100 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on August 26, 2016.

Medtronic plc (NYSE:MDT): After opening at $84.66, the stock dipped to an intraday low of $84.38 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $85.995 and the buying power remained strong till the end. The stock closed at $85.66 for the day, a gain of 1.16% for the day session. The total traded volume was 4,703,058. The stocks close on the previous trading day was $84.68.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.